EMEA-003309-PIP01-22
Submitted by Anonymous (not verified) on 11 January 2024 - 13:14
EMEA-003309-PIP01-22
EMEA-002840-PIP02-22
Submitted by Anonymous (not verified) on 11 January 2024 - 13:12
EMEA-002840-PIP02-22
EMEA-002798-PIP03-22
Submitted by Anonymous (not verified) on 11 January 2024 - 13:02
EMEA-002798-PIP03-22
EMEA-002698-PIP03-22
Submitted by Anonymous (not verified) on 11 January 2024 - 12:49
EMEA-002698-PIP03-22
EMEA-002698-PIP02-22
Submitted by Anonymous (not verified) on 11 January 2024 - 12:38
EMEA-002698-PIP02-22
Scientific guidelines with summary-of-product-characteristics recommendations
Submitted by Anonymous (not verified) on 11 January 2024 - 12:30
Scientific guidelines with summary-of-product-characteristics recommendations
IRIS guide to registration and RPIs
Submitted by Anonymous (not verified) on 11 January 2024 - 12:15
IRIS guide to registration and RPIs
Recommended submission dates for veterinary medicinal products
Submitted by Anonymous (not verified) on 11 January 2024 - 11:54
Recommended submission dates for veterinary medicinal products
EMEA-003119-PIP01-21-M01
Submitted by Anonymous (not verified) on 11 January 2024 - 10:50
EMEA-003119-PIP01-21-M01
Opinion/decision on a Paediatric investigation plan (PIP): Emgality, Galcanezumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0030/2023
Submitted by Anonymous (not verified) on 11 January 2024 - 10:40
Opinion/decision on a Paediatric investigation plan (PIP): Emgality, Galcanezumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0030/2023